Bulletin from Annual General Meeting of Diamyd Medical AB
STOCKHOLM -- December 06, 2012
The following items were addressed at the Annual General Meeting of Diamyd
Medical AB (publ) (STO:DIAM.B)(Pink Sheets:DMYDY) held today:
Diamyd Medical's President and CEO Peter Zerhouni gave a retrospective view of
the past year and summarized the most significant events that took place
during the fiscal year and after year-end.
The Company's income statements and balance sheets were adopted and the Board
members and the Chief Executive Officer were discharged from liability for the
2011/2012 fiscal year. The Annual General Meeting approved the Board's
proposal that no dividend be paid for the 2011/2012 fiscal year.
Anders Essen-Möller was re-elected as Chairman of the Board and Maria-Teresa
Essen-Möller was re-elected to the Board. Erik Nerpin and Jonas Jendi were
elected as new Board members. Erik Nerpin, born in 1961, is an attorney and
partner at Kilpatrick Townsend in Stockholm. Jonas Jendi, born in 1970, M.Sc.
Economics & Business Administration, has spent the last 10 years managing the
company Cogmed. Cogmed is based on research from the Karolinska Institute and
was acquired by Pearson in 2010. The former Board members Lars Jonsson, Joseph
Janes and Christer Lindberg have declined re-election.
The Annual General Meeting approved the proposed guidelines for remuneration
of the CEO and other senior executives. The Meeting also approved the proposed
remuneration to Board members and the Chairman of the Board.
The Annual General Meeting resolved to re-elect the auditing company Öhrlings
PricewaterhouseCoopers until the end of the Annual General Meeting 2013.
Principal auditor is the authorized public accountant Eva Blom.
The Annual General Meeting approved the proposed principles for the
appointment of Nomination Committee for the 2013 Annual General Meeting.
The Annual General Meeting resolved to authorize the Board to approve new
share issues for a maximum total of 10 percent of the number of shares on one
or more occasions before the next Annual General Meeting, and permit the Board
to deviate from the shareholders’ preferential rights when so doing. Payment
may be made in cash, through a contribution or by offsetting.
The Annual General Meeting resolved to authorize the Board, for the period
until the next Annual General Meeting, to repurchase series B shares in Diamyd
Medical on Nasdaq OMX Stockholm. The maximum number of shares repurchased
shall be such that Diamyd Medical shares held in treasury from time to time do
not exceed ten percent of all shares in Diamyd Medical.
About Diamyd Medical
Diamyd Medical was founded in 1996 and is active in the field of
pharmaceutical development. Diamyd Medical is headquartered in Stockholm,
Sweden. The Company’s development project consists of the protein GAD65 for
the treatment and prevention of autoimmune diabetes. A Swedish
researcher-initiated Phase II study is ongoing to evaluate whether GAD65 can
prevent type 1 diabetes in children who are at high risk of developing the
Diamyd Medical also has holdings in the gene therapy company Periphagen
Holdings, Inc. (USA), the vaccine company Protein Sciences Corporation (USA)
and the diagnostics company Mercodia AB (Sweden).
Diamyd shares are listed on Nasdaq OMX (segment Small Cap) in Stockholm
(ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the
Pink OTC Markets and the Bank of New York Mellon (PAL). Further information is
available on the Company’s website: www.diamyd.com.
This information is disclosed in accordance with the Swedish Securities
Markets Act, the Swedish Financial Instruments Trading Act, or the
requirements stated in the listing agreements.
Diamyd Medical AB (publ) Karlavägen 108, SE-115 26 Stockholm, Sweden. Phone:
+46 8 661 00 26, Fax: +46 8 661 63 68 E-mail: email@example.com. Reg. no:
This information was brought to you by Cision http://www.cisionwire.com
Diamyd Medical AB
Peter Zerhouni, President and CEO
Phone: +46 8 661 00 26
Press spacebar to pause and continue. Press esc to stop.